Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Department of Pharmacy, Peking University International Hospital, Beijing, China.
Sci Prog. 2021 Jan-Mar;104(1):368504211000535. doi: 10.1177/00368504211000535.
Drug-induced liver injury (DILI) is one of the common adverse drug reactions and the leading cause of drug development attritions, black box warnings, and post-marketing withdrawals. Current biomarkers are suboptimal in detecting DILI and predicting its outcome. This study aimed to quantitatively and qualitatively investigate the research trends on DILI biomarkers using bibliometric analysis. All relevant publications were extracted from the Web of Science database. An online analysis platform of literature metrology, bibliographic item co-occurrence matrix builder, and CiteSpace software were used to analyze the publication trends. CitNetExplorer was used to construct direct citation networks and VOSviewer was used to analyze the keywords and research hotspots. We found a total of 485 publications related to DILI biomarkers published from 1991 to 2020. had been the most popular journal in this field over the past 30 years. The USA maintained a top position worldwide and provided a pivotal influence, followed by China. Among all the institutions, the University of Liverpool was regarded as a leader for research collaboration. Moreover, Professors Paul B. Watkins and Tsuyoshi Yokoi made great achievements in topic area. We analyzed the citation networks and keywords, therefore identified five and six research hotspot clusters, respectively. We considered the publication information regarding different countries/regions, organizations, authors, journals, et al. by summarizing the literature on DILI biomarkers over the past 30 years. Notably, the subject of DILI biomarkers is an active area of research. In addition, the investigation and discovery of novel promising biomarkers such as microRNAs, keratin18, and bile acids will be future developing hotspots.
药物性肝损伤（DILI）是常见的药物不良反应之一，也是药物研发失败、黑框警告和上市后撤市的主要原因。目前的生物标志物在检测 DILI 和预测其结局方面并不理想。本研究旨在通过文献计量学分析定量和定性研究 DILI 生物标志物的研究趋势。从 Web of Science 数据库中提取所有相关文献。使用文献计量在线分析平台、书目项共现矩阵构建器和 CiteSpace 软件分析出版趋势。使用 CitNetExplorer 构建直接引文网络，使用 VOSviewer 分析关键词和研究热点。我们共发现了 1991 年至 2020 年与 DILI 生物标志物相关的 485 篇出版物。在过去的 30 年中，[杂志名称]一直是该领域最受欢迎的期刊。美国在全球范围内保持领先地位，并具有关键影响力，其次是中国。在所有机构中，利物浦大学被认为是研究合作的领导者。此外，Paul B. Watkins 教授和 Tsuyoshi Yokoi 教授在主题领域取得了巨大成就。我们分析了引文网络和关键词，因此分别确定了五个和六个研究热点群。通过总结过去 30 年关于 DILI 生物标志物的文献，我们考虑了不同国家/地区、组织、作者、期刊等的出版信息。值得注意的是，DILI 生物标志物的主题是一个活跃的研究领域。此外，对 microRNAs、角蛋白 18 和胆汁酸等新型有前途的生物标志物的研究和发现将成为未来的发展热点。
